Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination

详细信息    查看全文

• 作者：Kunitoshi Shigeyasu (1)
  Shunsuke Kagawa (1)
  Futoshi Uno (1)
  Masahiko Nishizaki (1)
  Hiroyuki Kishimoto (1)
  Akira Gochi (1)
  Toshikazu Kimura (2)
  Takaomi Takahata (2)
  Yasuyuki Nonaka (3)
  Motoki Ninomiya (4)
  Toshiyoshi Fujiwara (1)
  
• 关键词：Gastric cancer ; Peritoneal dissemination ; S ; 1 ; Docetaxel ; Phase II study
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2013
• 出版时间：April 2013
• 年：2013
• 卷：71
• 期：4
• 页码：937-943
• 全文大小：187KB
• 参考文献：1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-150 CrossRef
  2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10-0 CrossRef
  3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-1 CrossRef
  4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-91 CrossRef
  5. MacDonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R, Lagarde C (1980) 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93:533-36
  6. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H et al (1994) A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5:609-16
  7. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54-9 CrossRef
  8. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-997 CrossRef
  9. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O’Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-67
  10. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-57 CrossRef
  11. Diasio RB (1999) Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Williston Park) 13:17-1
  12. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063-069 CrossRef
  13. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-21 CrossRef
  14. Einzig AI, Neuberg D, Remick SC, Karp DD, O’Dwyer PJ, Stewart JA, Benson AB 3rd (1996) Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13:87-3 CrossRef
  15. Thuss-Patience PC, Kretzschmar A, Reichardt P (2006) Docetaxel in the treatment of gastric cancer. Future Oncol 2:603-20 CrossRef
  16. Fushida S, Fujimura T, Oyama K, Yagi Y, Kinoshita J, Ohta T (2009) Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases. Anticancer Drugs 20:752-56 CrossRef
  17. Zang DY, Yang DH, Kim MJ, Jang KM, Hwang SW, Yoo KS, Han T, Kim HY, Kim HJ, Kwon JH, Song HH, Park S, Jung JY, Kim HS, Kim JH (2009) Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer. Cancer Chemother Pharmacol 64:877-83 CrossRef
  18. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3402-407 CrossRef
  19. Kunisaki C, Takahashi M, Makino H, Oshima T, Fujii S, Takagawa R, Kimura J, Kosaka T, Ono HA, Akiyama H, Kameda K, Kito F, Morita S, Endo I (2011) Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer. Cancer Chemother Pharmacol 67:1363-368 CrossRef
  20. Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, Araki K (2006) Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol 12:1412-415
  21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-47 CrossRef
  22. Japanese Gastric Cancer Association (2001) Japanese classification of gastric carcinoma-nd English edition–response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. Gastric Cancer 4:1- CrossRef
  23. Lawless J (1982) Statistical models and methods for lifetime data. Wiley, New York
  24. Yamao T, Shimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I, Saito H, Iwase H, Tsuji Y, Tamura T, Yamamoto S, Yoshida S (2004) Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol 34:316-22 CrossRef
  25. Tahara M, Ohtsu A, Boku N, Nagashima F, Muto M, Sano Y, Yoshida M, Mera K, Hironaka S, Tajiri H, Yoshida S (2001) Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with peritoneal dissemination: a retrospective study. Gastric Cancer 4:212-18 CrossRef
  26. Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58:191-97 CrossRef
  27. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1?M tegafur-0.4?M gimestat-1?M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-720 CrossRef
  28. Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C, Sakata Y (2011) Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 14:72-0 CrossRef
  29. Ishigami H, Kitayama J, Kaisaki S, Yamaguchi H, Yamashita H, Emoto S, Nagawa H (2010) Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis. Oncology 79:269-72 CrossRef
  30. Van Den Neste E, de Valeriola D, Kerger J, Bleiberg H, Kusenda Z, Brassinne C, Bartholomeus S, Selleslags J, Hennebert P, Wythouck H, Cazenave I, Lefresne-Soulas F, Piccart M (2000) A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res 6:64-1
  31. Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, Hirabayashi N (1998) Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A). Gan To Kagaku Ryoho 25:1915-924
  32. Fujii M (2008) Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). Int J Clin Oncol 13:201-05 CrossRef
  
• 作者单位：Kunitoshi Shigeyasu (1)
  Shunsuke Kagawa (1)
  Futoshi Uno (1)
  Masahiko Nishizaki (1)
  Hiroyuki Kishimoto (1)
  Akira Gochi (1)
  Toshikazu Kimura (2)
  Takaomi Takahata (2)
  Yasuyuki Nonaka (3)
  Motoki Ninomiya (4)
  Toshiyoshi Fujiwara (1)
  
  1. Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan
  2. Department of Surgery, Okayama Saiseikai General Hospital, Okayama, Japan
  3. Department of Surgery, Tsuyama Chuo Hospital, Tsuyama, Japan
  4. Department of General Surgery, Hiroshima City Hospital, Hiroshima, Japan
  
• ISSN：1432-0843

文摘

Purpose Peritoneal dissemination is the most frequent and life-threatening mode of metastasis and recurrence in patients with gastric cancer. A multicenter phase II study was designed to evaluate the efficacy and tolerability of S-1 and docetaxel combination chemotherapy regimen for the treatment of advanced or recurrent gastric cancer patients with peritoneal dissemination. Methods Nineteen patients with histologically confirmed unresectable or recurrent gastric cancer with peritoneal dissemination were enrolled. Oral S-1 at 80?mg/m2/day was administered twice daily for 2?weeks, followed by 1 drug-free week. Docetaxel infusion at 40?mg/m2 was performed on day 1, simultaneous with S-1 administration. The primary endpoints were overall survival (OS) and time to progression (TTP). The secondary endpoints were the response rates and safety status. Results Patients received a median of 4 cycles of the S-1 and docetaxel regimen (range 1-3). The disease control rate was 73.7?% (14/19). Median overall survival was 459?days (15.3?months), while median time to progression was 212?days (7.1?months). Neutropenia was the most common type of toxicity (n?=?7, 36.8?%). Conclusions Combination chemotherapy with S-1 and docetaxel is a tolerable and effective treatment for advanced or recurrent gastric cancer patients with peritoneal dissemination.